Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 39 - General protective or antinoxious agents
Patents for A61P 39 - General protective or antinoxious agents (19,019)
10/2003
10/15/2003EP1351688A1 Urotensin-ii receptor antagonists
10/15/2003EP1351687A2 Urotensin-ii receptor antagonists
10/15/2003EP1351679A2 Method and composition for the treatment of diabetic neuropathy
10/15/2003EP1351677A2 Method for treating cancer
10/15/2003EP1351663A1 Cosmetic and/or pharmaceutical preparations
10/15/2003EP1351662A1 Cosmetic and/or pharmaceutical preparations
10/15/2003EP1135103B1 Use of plant extracts with an anti-radical-type action and cosmetic or dermopharmaceutical composition comprising such extracts
10/15/2003EP0956019B1 Novel therapeutic application of a thienycyclohexylamine derivative
10/15/2003EP0876140B1 Improved kontrast agent solutions for intravenous administration
10/15/2003CN1449284A 维生素c组合物 Vitamin c composition
10/09/2003WO2003082813A2 Improvements in pharmaceutical compositions
10/09/2003WO2003082296A1 Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
10/09/2003WO2003082281A1 Obidoxime dimesylate
10/09/2003WO2003082239A1 Use of compatible solutes for inhibiting the release of ceramides
10/09/2003WO2002078682A3 Estrogen replacement therapy
10/09/2003WO2002056905A3 Molecular antigen array
10/09/2003US20030191170 Central nervous system disorders; antiallergens; respiratory system disorders
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190372 Cough depressant composition containing iron for angiotensin-converting enzyme inhibitor inducing cough
10/09/2003US20030190331 Vaccine composition and stabilisation method
10/09/2003CA2480857A1 Improvements in pharmaceutical compositions
10/08/2003EP1349964A2 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests
10/08/2003EP1349864A2 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
10/08/2003CN1123358C Oral liquid for treating cerebrovascular disease
10/07/2003US6630507 Cannabinoids as antioxidants and neuroprotectants
10/02/2003WO2003080842A1 Zearalenone-detoxifying enzyme gene and transformant having the gene transferred thereinto
10/02/2003WO2003080619A1 Fused bicyclic pyrimidine derivatives
10/02/2003WO2003080581A1 Phenanthridinones as parp inhibitors
10/02/2003WO2003080090A1 Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450
10/02/2003WO2003080087A1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation
10/02/2003WO2003080063A1 PREVENTIVES OR REMEDIES FOR DISEAES CAUSED BY eNOS EXPRESSION
10/02/2003WO2003080047A1 Phosphate prodrugs of fluorooxindoles
10/02/2003WO2002074323A3 Using neural thread proteins to treat tumors and other hyperproliferative disorders
10/02/2003WO2002022573A3 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
10/02/2003US20030186958 Viricides, vision defects, oral diseases, antiarthritic agents, multiple sclerosis, anticancer agents
10/02/2003US20030186941 Cyclopenteneone derivatives
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186891 Polypeptide comprising fragments of matrix extracellular phosphoglycoproteins used to control calcitriol concentrations in cells, for prophylaxis of bone disorders
10/02/2003US20030186839 Medicinal compositions
10/02/2003US20030185921 Optionally esterified 5-ethylidene-4-carboxy-2-pyranones as a cytoprotective agent
10/02/2003US20030185869 Having lysozyme adsorbed onto or associated with the surface of an active agent
10/02/2003CA2480384A1 Phenanthridinones as parp inhibitors
10/02/2003CA2480334A1 Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450
10/02/2003CA2479277A1 Fused bicyclic pyrimidine derivatives
10/02/2003CA2479256A1 Phosphate prodrugs of fluorooxindoles
10/02/2003CA2451516A1 Agent for preventing or treating diseases caused by enos expression
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347805A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
10/01/2003EP1347768A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
10/01/2003CN1446101A Combination product comprising melagatran and factor VLLa inhibitor
09/2003
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627231 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/25/2003WO2002020846A3 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
09/25/2003US20030181529 Method for preventing and treating peripheral neuropathy by administering selegiline
09/25/2003US20030181527 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof
09/25/2003US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030180308 Deglycosylated ricin toxin a-chain vaccine
09/25/2003US20030180231 Cosmetics, skin disorders; sunscreen agents; aging resistance
09/25/2003US20030180179 Adsorber containing silver particles; chemical and biological warfare
09/25/2003CA2828595A1 Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
09/25/2003CA2478997A1 Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
09/24/2003EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
09/24/2003EP1345933A2 Process for making substituted 8-arylquinolinium benzenesulfonate
09/24/2003EP1345902A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same
09/24/2003EP1345895A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
09/24/2003EP1345616A2 Reducing cellular damage in the human body
09/24/2003CN1444475A Preparation with vascular protective and anti-oxidative effect and use thereof
09/24/2003CN1121856C Composite coenzyme Q10 medicine
09/23/2003US6624295 Heavy chain and light chain peptides comprising complement determining regions, including single chain FV fragments, used as thrombolytic agents
09/23/2003CA2281570C Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
09/23/2003CA2073633C Use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas
09/18/2003WO2003076617A1 Transporter selectively transporting sulfate conjugate and its gene
09/18/2003WO2003076565A2 Methods of using 46828, a human acyl-coa synthetase
09/18/2003WO2003076407A1 Novel chalcone derivatives and uses thereof
09/18/2003WO2003076406A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
09/18/2003WO2003075939A1 Soybean saponin-containing material and process for producing the same
09/18/2003WO2003075903A2 Use proline and its functional equivalentsfor quenching ros and/ or radicals
09/18/2003WO2003075861A1 Antioxidative preparations
09/18/2003WO2003075850A2 Methods for alzheimer's disease treatment and cognitive enhancement
09/18/2003WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
09/18/2003WO2003051893A3 Improvements in pharmaceutical compositions
09/18/2003WO2003051807A3 Improvements in pharmaceutical compositions
09/18/2003WO2003041499A3 Bactericides based on metal-chelate complexes and disinfecting composition
09/18/2003WO2002078627A3 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
09/18/2003WO2002077174A3 Human cytokine receptor
09/18/2003US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer
09/18/2003US20030176486 For use as an inhibitor of lipopolysaccharides (LPS)
09/18/2003US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
09/18/2003US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof
09/18/2003US20030175711 Comprises ordered and repetitive antigen or antigenic determinant array for developing vaccines for treatment of infectious diseases, allergies and cancer; microarrays
09/18/2003US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents
09/18/2003US20030175334 Phospholipid bodies and use thereof in medical treatment
09/18/2003US20030175290 Molecular antigen array
1 ... 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 ... 191